John York and colleagues have demonstrated that the protein Vip1 is a rare type of bifunctional enzyme: it can both synthesize and destroy key cellular signaling molecules.

Understanding how MYC interacts with WDR5 and other cofactors could lead to the development of new drugs that can effectively block MYC and stop many cancers in their tracks.

An unprecedented view of bacterial products within infected tissues opens new opportunities to explore infection biology and devise novel therapeutic strategies.

Immune cells that produce an anti-inflammatory factor are enriched in fat tissue around the heart and may be good targets to improve heart attack outcomes.

New research findings provide insight into the detrimental events that develop in response to H. pylori infection.

Mark Boothby and colleagues are exploring the factors that contribute to antibody production and quality, which are key to our defense against pathogens and response to vaccines.

A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.